 Alpine Immune Sciences Inc NASDAQ: ALPN has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology EULAR European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody. 